Abstract
IF THE CONTRACT manufacturing and service firms attending CPhI, the annual conference on pharmaceutical ingredients, expressed a guarded optimism, it is partly because they have lowered their expectations. The pharmaceutical chemicals sector is showing signs of recovery from a steep drop in business in 2009. But business managers in Paris, where the meeting was held earlier this month, agreed that the double-digit growth rates of 2007 and 2008 for contract-manufactured small-molecule and biologic active pharmaceutical ingredients (APIs) are not likely to return this year or next. The sector remains focused on a mix of pharmaceutical industry trends that predate the recession. These include an increase in outsourcing by major drug companies and the chronic doldrums in big pharma’s smallmolecule drug pipeline. The big drug firms are compensating for lack of innovation in the lab by expanding their biotech portfolios. As a result, some contract manufacturers are planning to boost biotech offerings or invest ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
